Leucoreduction of blood components: an effective way to increase blood safety?

Maria Bianchi^{1

2}, Stefania Vaglio^{1

3}, Simonetta Pupella¹, Giuseppe Marano¹, Giuseppina Facco^{1

4}, Giancarlo M Liumbruno¹, Giuliano Grazzini¹

Affiliations

¹ Italian National Blood Centre, National Institute of Health, Rome, Italy.
² Blood Transfusion Service, "A. Gemelli" University Polyclinic, "Sacro Cuore" Catholic University, Rome, Italy.
³ Faculty of Medicine and Psychology, "Sapienza" University of Rome, Rome, Italy.
⁴ Immunohaemathology and Transfusion Medicine Unit, "Città della Salute e della Scienza" Hospital, Turin, Italy.

PMID: 26710353
PMCID: PMC4918553
DOI: 10.2450/2015.0154-15

Review

Leucoreduction of blood components: an effective way to increase blood safety?

Maria Bianchi et al. Blood Transfus. 2016 May.

. 2016 May;14(2):214-27.

doi: 10.2450/2015.0154-15. Epub 2015 Dec 16.

Authors

Maria Bianchi^{1

2}, Stefania Vaglio^{1

3}, Simonetta Pupella¹, Giuseppe Marano¹, Giuseppina Facco^{1

4}, Giancarlo M Liumbruno¹, Giuliano Grazzini¹

Affiliations

¹ Italian National Blood Centre, National Institute of Health, Rome, Italy.
² Blood Transfusion Service, "A. Gemelli" University Polyclinic, "Sacro Cuore" Catholic University, Rome, Italy.
³ Faculty of Medicine and Psychology, "Sapienza" University of Rome, Rome, Italy.
⁴ Immunohaemathology and Transfusion Medicine Unit, "Città della Salute e della Scienza" Hospital, Turin, Italy.

PMID: 26710353
PMCID: PMC4918553
DOI: 10.2450/2015.0154-15

Abstract

Over the past 30 years, it has been demonstrated that removal of white blood cells from blood components is effective in preventing some adverse reactions such as febrile non-haemolytic transfusion reactions, immunisation against human leucocyte antigens and human platelet antigens, and transmission of cytomegalovirus. In this review we discuss indications for leucoreduction and classify them into three categories: evidence-based indications for which the clinical efficacy is proven, indications based on the analysis of observational clinical studies with very consistent results and indications for which the clinical efficacy is partial or unproven.

PubMed Disclaimer

Comment in

Leucoreduction of blood components: clinical and molecular evidence.
D'alessandro A. D'alessandro A. Blood Transfus. 2016 May;14(2):212-3. doi: 10.2450/2015.0291-15. Epub 2015 Dec 16. Blood Transfus. 2016. PMID: 26710355 Free PMC article. No abstract available.

Comment on

Prevention of alloimmunization in patients with acute leukemia by use of white cell-reduced blood components--a randomized trial.
Oksanen K, Kekomäki R, Ruutu T, Koskimies S, Myllylä G. Oksanen K, et al. Transfusion. 1991 Sep;31(7):588-94. doi: 10.1046/j.1537-2995.1991.31791368333.x. Transfusion. 1991. PMID: 1891788 Clinical Trial.
Bedside filtration of blood products in the prevention of HLA alloimmunization--a prospective randomized study. Alloimmunisation Study Group.
Williamson LM, Wimperis JZ, Williamson P, Copplestone JA, Gooi HC, Morgenstern GR, Norfolk DR. Williamson LM, et al. Blood. 1994 May 15;83(10):3028-35. Blood. 1994. PMID: 8180400 Clinical Trial.
The effect of prestorage WBC reduction on the rates of febrile nonhemolytic transfusion reactions to platelet concentrates and RBC.
Yazer MH, Podlosky L, Clarke G, Nahirniak SM. Yazer MH, et al. Transfusion. 2004 Jan;44(1):10-5. doi: 10.1046/j.0041-1132.2003.00518.x. Transfusion. 2004. PMID: 14692961
Reduction of febrile but not allergic reactions to RBCs and platelets after conversion to universal prestorage leukoreduction.
Paglino JC, Pomper GJ, Fisch GS, Champion MH, Snyder EL. Paglino JC, et al. Transfusion. 2004 Jan;44(1):16-24. doi: 10.1046/j.0041-1132.2004.00608.x. Transfusion. 2004. PMID: 14692962
Universal leukoreduction decreases the incidence of febrile nonhemolytic transfusion reactions to RBCs.
King KE, Shirey RS, Thoman SK, Bensen-Kennedy D, Tanz WS, Ness PM. King KE, et al. Transfusion. 2004 Jan;44(1):25-9. doi: 10.1046/j.0041-1132.2004.00609.x. Transfusion. 2004. PMID: 14692963
Transfusion of leukoreduced red blood cells may decrease postoperative infections: two meta-analyses of randomized controlled trials.
Fergusson D, Khanna MP, Tinmouth A, Hébert PC. Fergusson D, et al. Can J Anaesth. 2004 May;51(5):417-24. doi: 10.1007/BF03018302. Can J Anaesth. 2004. PMID: 15128625
Factors affecting posttransfusion platelet increments, platelet refractoriness, and platelet transfusion intervals in thrombocytopenic patients.
Slichter SJ, Davis K, Enright H, Braine H, Gernsheimer T, Kao KJ, Kickler T, Lee E, McFarland J, McCullough J, Rodey G, Schiffer CA, Woodson R. Slichter SJ, et al. Blood. 2005 May 15;105(10):4106-14. doi: 10.1182/blood-2003-08-2724. Epub 2005 Feb 3. Blood. 2005. PMID: 15692069 Free PMC article. Clinical Trial.
Transfusion of leukoreduced cellular blood components from cytomegalovirus-unscreened donors in allogeneic hematopoietic transplant recipients: analysis of 72 recipients.
Narvios AB, de Lima M, Shah H, Lichtiger B. Narvios AB, et al. Bone Marrow Transplant. 2005 Sep;36(6):499-501. doi: 10.1038/sj.bmt.1705090. Bone Marrow Transplant. 2005. PMID: 16044143
The intention-to-treat principle in clinical trials and meta-analyses of leukoreduced blood transfusions in surgical patients.
Blumberg N, Zhao H, Wang H, Messing S, Heal JM, Lyman GH. Blumberg N, et al. Transfusion. 2007 Apr;47(4):573-81. doi: 10.1111/j.1537-2995.2007.01158.x. Transfusion. 2007. PMID: 17381614
Effects of blood transfusion with leucocyte depletion on length of hospital stay, respiratory assistance and survival after curative surgery for colorectal cancer.
Skånberg J, Lundholm K, Haglind E. Skånberg J, et al. Acta Oncol. 2007;46(8):1123-30. doi: 10.1080/02841860701441830. Acta Oncol. 2007. PMID: 17851860 Clinical Trial.
Cause-specific mortality associated with leukoreduced, buffy coat-depleted, or no blood transfusion after elective surgery for colorectal cancer: a posttrial 15-year follow-up study.
Mortensen FV, Jensen LS, Sørensen HT, Pedersen L. Mortensen FV, et al. Transfusion. 2011 Feb;51(2):259-63. doi: 10.1111/j.1537-2995.2010.02825.x. Epub 2010 Aug 30. Transfusion. 2011. PMID: 20804531
All clinically-relevant blood components transmit prion disease following a single blood transfusion: a sheep model of vCJD.
McCutcheon S, Alejo Blanco AR, Houston EF, de Wolf C, Tan BC, Smith A, Groschup MH, Hunter N, Hornsey VS, MacGregor IR, Prowse CV, Turner M, Manson JC. McCutcheon S, et al. PLoS One. 2011;6(8):e23169. doi: 10.1371/journal.pone.0023169. Epub 2011 Aug 17. PLoS One. 2011. PMID: 21858015 Free PMC article.
Impact of leucocyte depletion and prion reduction filters on TSE blood borne transmission.
Lacroux C, Bougard D, Litaise C, Simmons H, Corbiere F, Dernis D, Tardivel R, Morel N, Simon S, Lugan S, Costes P, Weisbecker JL, Schelcher F, Grassi J, Coste J, Andréoletti O. Lacroux C, et al. PLoS One. 2012;7(7):e42019. doi: 10.1371/journal.pone.0042019. Epub 2012 Jul 31. PLoS One. 2012. PMID: 22860049 Free PMC article.
Safety of leukoreduced, cytomegalovirus (CMV)-untested components in CMV-negative allogeneic human progenitor cell transplant recipients.
Nash T, Hoffmann S, Butch S, Davenport R, Cooling L. Nash T, et al. Transfusion. 2012 Oct;52(10):2270-2. doi: 10.1111/j.1537-2995.2012.03739.x. Transfusion. 2012. PMID: 23110735 No abstract available.
Impact of more restrictive blood transfusion strategies on clinical outcomes: a meta-analysis and systematic review.
Salpeter SR, Buckley JS, Chatterjee S. Salpeter SR, et al. Am J Med. 2014 Feb;127(2):124-131.e3. doi: 10.1016/j.amjmed.2013.09.017. Epub 2013 Oct 7. Am J Med. 2014. PMID: 24331453
Experimental prestorage filtration removes antibodies and decreases lipids in RBC supernatants mitigating TRALI in vivo.
Silliman CC, Kelher MR, Khan SY, LaSarre M, West FB, Land KJ, Mish B, Ceriano L, Sowemimo-Coker S. Silliman CC, et al. Blood. 2014 May 29;123(22):3488-95. doi: 10.1182/blood-2013-10-532424. Epub 2014 Apr 18. Blood. 2014. PMID: 24747436 Free PMC article.
Lower versus higher hemoglobin threshold for transfusion in septic shock.
Holst LB, Haase N, Wetterslev J, Wernerman J, Guttormsen AB, Karlsson S, Johansson PI, Aneman A, Vang ML, Winding R, Nebrich L, Nibro HL, Rasmussen BS, Lauridsen JR, Nielsen JS, Oldner A, Pettilä V, Cronhjort MB, Andersen LH, Pedersen UG, Reiter N, Wiis J, White JO, Russell L, Thornberg KJ, Hjortrup PB, Müller RG, Møller MH, Steensen M, Tjäder I, Kilsand K, Odeberg-Wernerman S, Sjøbø B, Bundgaard H, Thyø MA, Lodahl D, Mærkedahl R, Albeck C, Illum D, Kruse M, Winkel P, Perner A; TRISS Trial Group; Scandinavian Critical Care Trials Group. Holst LB, et al. N Engl J Med. 2014 Oct 9;371(15):1381-91. doi: 10.1056/NEJMoa1406617. Epub 2014 Oct 1. N Engl J Med. 2014. PMID: 25270275 Clinical Trial.
Evaluation of the protection of primates transfused with variant Creutzfeldt-Jakob disease-infected blood products filtered with prion removal devices: a 5-year update.
Lescoutra-Etchegaray N, Jaffré N, Sumian C, Durand V, Correia E, Mikol J, Luccantoni-Freire S, Culeux A, Deslys JP, Comoy EE. Lescoutra-Etchegaray N, et al. Transfusion. 2015 Jun;55(6):1231-41. doi: 10.1111/trf.12999. Epub 2015 Feb 3. Transfusion. 2015. PMID: 25647476

References

1. Davenport RD, Snyder EL. Cytokines in transfusion medicine: a primer. Bethesda, MD: American Association of Blood Banks; 1997.
1. Fergusson D, Khanna MP, Tinmouth A, Hébert PC. Transfusion of leukoreduced red blood cells may decrease postoperative infections: two meta-analyses of randomized controlled trials. Can J Anaesth. 2004;51:417–24. - PubMed
1. Blumberg N, Zhao H, Wang H, et al. The intention-to-treat principle in clinical trials and meta-analyses of leukoreduced blood transfusions in surgical patients. Transfusion. 2007;47:573–81. - PubMed
1. Blajchman MA. The clinical benefits of the leucoreduction of blood products. J Trauma. 2006;60:S83–90. - PubMed
1. Bilgin YM, van de Watering LM, Brand A. Clinical effects of leucoreduction of blood transfusions. Neth J Med. 2011;69:441–50. - PubMed

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
Medical
- MedlinePlus Health Information
Miscellaneous
- NCI CPTAC Assay Portal

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Leucoreduction of blood components: an effective way to increase blood safety?

Affiliations

Leucoreduction of blood components: an effective way to increase blood safety?

Authors

Affiliations

Abstract

Comment in

Comment on

References

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Medical

Miscellaneous